EGFR and non-small cell lung carcinoma: Compared with the placebo group, median PFS (mPFS) of patients, treated with Apatinib was extended by 2.8 months.11,12 There are few studies exploring the clinical efficacy of Apatinib combined with EGFR-TKI in NSCLC after EGFR-TKI resistance.13 Therefore, this study aimed to assess the efficacy and safety of Apatinib combined with EGFR-TKI for treating NSCLC patients with EGFR-TKI resistance by comparing with chemotherapy.